The two companies are now in their honeymoon period.

GlaxoSmithKline now understands that this Xiangjiang Pumpkin Vine Pharmaceutical Company has unknown research power and can create and invent various hot new drugs.

For the sake of current interests and future cooperation, they are still willing to give in as long as they do not touch on the issue of principles.

For Pumpkin Vine Pharmaceutical Company, they can only be considered a rootless duckweed now. Their own strength is too weak, so weak that they have no external aid, and they may not even be able to play in Xiangjiang.

Don’t forget that this is still in 1986, and it’s still more than ten years before 97. Now the one who has the final say is still the foreigners, and the one who hangs the photos on the wall is still the one who “super long standby”.

Therefore, maintain good relationships with major pharmaceutical giants in the world, and if necessary, you can pretend to be powerful and maximize your interests.

Just like acquiring Margrit Hospital, if it weren't for GlaxoSmithKline, would people sell it to a small company that had little information and had no experience in hospital management?

Would you be willing to keep the price so low? Even if you have the money to acquire it, can you hand over the hospital smoothly without the full cooperation of GlaxoSmithKline?

Although Chen Xia gave up most of the benefits, he also gave him a lot of rewards.

Although the first patent fee has not been reported, it can be expected that the patent fee of the three companies will not be less than US$500 million a year.

$500 million, this is almost like a free pick for Chen Xia.

Moreover, the Huaguo and Xiangjiang markets are still in his hands, and these two markets are enough to make him become a fat man.

When China develops, I am afraid that it will end up eating until it is overwhelmed.

So although Chen Xia was not satisfied with the cooperation of patent authorization, he did not say too badly. Commercial negotiations were originally a process of mutual compromise.

"Mr. Chris, I think there is a little disagreement between us now. Regarding sildenafil, our idea was to produce and sell ourselves."

"Oh no, Chen, we are friends. You can't leave your friends behind, and without our help, it would be very, very difficult for you to open up the international market."

Chris became anxious when he heard this and quickly kindly "advice".

Of course, Chen Xia understood what this "advice" means, so he said with a smile, "So look, the differences are coming, our Pumpkin Vine Company cannot be controlled by you forever, right?"

Chris was about to explain something, but Chen Xia waved his hand:

"I know, from a business perspective, you don't want the pumpkin vines to develop too quickly. After all, colleagues are enemies, and you don't want to see another new competitor."

Chris nodded very honestly:

"You are right, Chen, you have to believe me. If your actions threaten those pharmaceutical giants, they have a way to make it difficult for you to move forward, even if there is a good medicine, it will be difficult to promote."

This is beautiful, and it seems to be from the perspective of the pumpkin vine and considering the pumpkin vine. In fact, the threats in it have not decreased at all.

Chen Xia thought for a while, "How about this, I have a new proposal. We can adopt a new model, that is, we cooperate with each other and set up a brand new wholly-owned company. How about it?"

Chris didn't expect Chen Xia to make such a proposal. He originally thought he would ask for an increase in patent fees.

"Chen, can you tell me this suggestion in detail? I can report to the board of directors. You know, I have no right to make a decision."

Chen Xia explained: "We two set up a wholly-owned company in Xiangjiang. We invest in patents. You invest in funds and sales channels. How to divide the specific equity? You can discuss it later. What do you think?"

This cooperation method is actually the most beneficial to pumpkin vines.

The first one can maximize profits. The reason why sildenafil is priced at high prices is because of its R&D costs. In fact, from the perspective of production costs, it is super cheap, but the selling price is super expensive and the profit is super high.

If we can cooperate in establishing a factory, the profit will be much higher than the patent fee of 5%, which is simply an astronomical amount.

Second, the cooperation with GlaxoSmithKline is closer, and the relationship between the two parties is more harmonious. As a British-funded company, they still have a big reputation in Xiangjiang and have to sell their face in every aspect.

This also helps Pumpkin Vine Pharmaceutical Company to develop steadily before 1997, so as not to be favored by any capitalist and then want to swallow Pumpkin Vine.

If you don’t have a backer, the Pumpkin Vine Company is simply vulnerable.

The two sides ended the first round of negotiations. Before Chris left, Chen Shuqin brought in a bag of small gifts from outside.

We are allies now, and we don’t have the total amount of small gifts to accept. Mr. He is still the medicine produced by Pumpkin Vine Company.

Of course, this medicine is a total of 20 boxes of sildenafil. Chris really wanted to shout: "It's my wish."

In fact, this is just the surface. Why are there only three of them on the scene during the negotiations? It is because some words can be said privately.

For example, Chen Shuqin promised that as long as Chris could facilitate the establishment of a joint venture between the two companies, the benefits of Pumpkin Vine Company could be maximized.

Then Chris will have an extra $2 million in a secret account in Switzerland.

How could Mr. Chris Grelin, the manager of GlaxoSmithKline, not love such a superb Pumpkin Vine Pharmaceutical Company?

How can you not help say good things at the board of directors or even mislead the board of directors that is beneficial to the Pumpkin Vine Company?

$2 million won't make him desperate, but it will definitely make him the best "complice".

Two weeks later, after multiple rounds of negotiations, the two sides finally reached a commercial agreement that both parties were satisfied with:

GlaxoSmithKline in England acquires Pumpkin Vine in Tsuen Wan Industrial Zone for US$200 million.

This item alone made Pumpkin Vines a big profit. Don’t forget that the acquisition was only 70 million Hong Kong dollars, less than 10 million US dollars.

In addition, GlaxoSmithKline invested US$200 million and Pumpkin Vine Pharmaceutical Company provided the patent for sildenafil, and the two parties established a brand new pharmaceutical factory - Tsuen Wan Pharmaceutical.

GlaxoSmithKline holds 75% of the shares and has an absolute controlling stake;

Pumpkin Vine holds 25% of the stake, and there is nothing else except financial supervision. Anyway, GlaxoSmithKline is more experienced in the pharmaceutical management.

As for the old employees of the former Australasian Pharmaceutical Factory, Ye Shirong and others, they were asked to stay in the mainland with peace of mind. All the pharmaceutical factories in Xiangjiang were sold, and the mainland will develop as a production base in the future.

This equity seems to be a big loss for Pumpkin Vine. After all, the drug sildenafil is sold at least billions or even tens of billions of dollars a year.
Chapter completed!